How should I manage a patient currently taking prednisone and dapagliflozin (Farxiga) who is not on an ACE inhibitor or ARB?

Management of a Patient on Prednisone and Farxiga Without ACE/ARB

You should strongly consider initiating an ACE inhibitor or ARB in this patient, as these medications are foundational therapy for most conditions requiring SGLT2 inhibitor treatment and provide critical cardiovascular and renal protection that prednisone and dapagliflozin alone cannot deliver.

Clinical Context Assessment

First, determine why this patient is on dapagliflozin (Farxiga), as this fundamentally changes management:

If for Heart Failure with Reduced Ejection Fraction (HFrEF):

• ACE inhibitor or ARB is Class I, Level A recommendation 1
• The 2022 AHA/ACC/HFSA guidelines mandate renin-angiotensin system (RAS) inhibition as one of the four pillars of GDMT for HFrEF, alongside beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors 1
• ARNi (sacubitril/valsartan) is preferred over ACE/ARB for NYHA class II-III patients if tolerated 1
• The absence of ACE/ARB represents a significant gap in guideline-directed therapy that increases mortality and morbidity risk 2

If for Chronic Kidney Disease:

• ACE inhibitor or ARB is first-line therapy for proteinuria reduction and slowing CKD progression 3
• KDIGO 2021 guidelines recommend uptitrating ACE/ARB to maximally tolerated doses as first-line therapy for patients with proteinuria 3
• Target blood pressure <120 mmHg systolic using standardized office measurement 3
• Do not stop ACE/ARB for modest, stable creatinine increases up to 30% 3

If for Type 2 Diabetes with Cardiovascular Risk:

• ACE/ARB remains indicated for blood pressure control and cardiovascular protection 4
• Multiple hypertension guidelines recommend ACE/ARB as preferred agents in diabetic patients 4

Prednisone-Specific Considerations

Prednisone creates additional urgency for RAS blockade:

• Corticosteroids cause sodium retention, volume expansion, and hypertension
• They increase cardiovascular risk and can worsen proteinuria
• The combination of prednisone with dapagliflozin without RAS blockade leaves the patient vulnerable to volume-related complications
• Monitor for volume depletion carefully when combining diuretic effects of dapagliflozin with potential volume shifts from prednisone 5

Practical Implementation Algorithm

Step 1: Assess Contraindications to ACE/ARB

Check for:

• History of angioedema with ACE inhibitors
• Bilateral renal artery stenosis
• Pregnancy or planning pregnancy
• Serum potassium >5.0 mEq/L
• eGFR <25 mL/min/1.73m² (relative, not absolute contraindication) 3

Step 2: Choose Agent Based on Primary Indication

For HFrEF:

• First choice: ARNi (sacubitril/valsartan) starting 24-26/51 mg twice daily 1
• Second choice: ACE inhibitor (enalapril, lisinopril, ramipril) at evidence-based doses 1
• Third choice: ARB (candesartan 4-8 mg daily or valsartan 40 mg twice daily) if ACE inhibitor not tolerated 2

For CKD/Proteinuria:

• ACE inhibitor or ARB equally acceptable as first-line 3
• Uptitrate to maximum tolerated dose targeting proteinuria <1 g/day 3
• ARB may be preferred in type 2 diabetes with nephropathy 6, 7

For Hypertension/Diabetes:

• Either ACE inhibitor or ARB acceptable 4
• ARB if prior ACE inhibitor cough 4

Step 3: Initiation Protocol

Before starting:

• Check baseline potassium, creatinine, eGFR
• Assess volume status (especially important with concurrent prednisone and dapagliflozin) 3, 5
• Counsel patient to hold medication during volume depletion ("sick day rules") 3

Monitoring schedule:

• Recheck potassium and creatinine at 1 week, then 4 weeks after initiation 2, 3
• Recheck at 1 and 4 weeks after each dose increase 2
• Accept creatinine increases up to 30% if stable 3

Step 4: Dose Titration

• Increase dose every 2-4 weeks as tolerated 2
• Target evidence-based doses, not just blood pressure control
• For HFrEF: candesartan 32 mg daily or valsartan 160 mg twice daily 2
• For CKD: maximize dose for proteinuria reduction 3

Critical Pitfalls to Avoid

Do not:

• Combine ACE inhibitor + ARB + aldosterone antagonist (triple RAS blockade) - this is contraindicated 2
• Start ACE/ARB in patients with abrupt-onset nephrotic syndrome (risk of AKI, especially with minimal change disease) 3
• Discontinue for modest creatinine elevation <30% 3
• Forget to counsel about sick day rules (hold during vomiting, diarrhea, reduced oral intake) 3

Monitor closely for:

• Hyperkalemia (use potassium-wasting diuretics or binders if needed to continue RAS blockade) 3
• Volume depletion (triple risk: prednisone effects + dapagliflozin diuresis + ACE/ARB) 5
• Acute kidney injury during intercurrent illness 3

Special Consideration: Prednisone-Induced Hyperglycemia

One small study showed dapagliflozin did not improve glycemic control better than placebo in prednisone-induced hyperglycemia during COPD exacerbations 8. However, this does not negate the cardiovascular and renal benefits of dapagliflozin for its approved indications. The lack of ACE/ARB remains the primary therapeutic gap requiring correction.

The bottom line: Unless there is a specific contraindication, this patient needs ACE inhibitor or ARB therapy initiated promptly, with preference for ARNi if the indication is HFrEF.